NCT05054088

ImmuneSense COVID-19 Variant Study

ImmuneSense™ COVID-19 Variant Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 203 (actual)
• Sponsor: Adaptive Biotechnologies · Industry
• Sex: All
• Age: 18 Years – 89 Years
• Healthy volunteers: Accepted

Summary

This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including newly emerging strains of SARS-CoV-2 and their prevalence, which changes over time.

Conditions

• Covid19

Interventions

Type	Name	Description
DEVICE	T-Detect COVID test	• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.

Timeline

• Start date: 2021-10-12
• Primary completion: 2022-07-20
• Completion: 2022-07-28
• First posted: 2021-09-23
• Last updated: 2022-12-07

Locations

15 sites across 1 country: United States